Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether intravenous immunoglobulin (IVIG) changes SJS/TEN‐specific mortality (time to compared with no IVIG (very low certainty).
1 finding from 1 review
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1 finding from 1 review
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1 finding from 1 review
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in BMI · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
H2 antagonists showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).
1 finding from 1 review
Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Nausea · people with schizophrenia with antipsychotic‐induced weight gain
H2 antagonists showed no clear difference in reports of nausea compared with placebo (low certainty).
1 finding from 1 review
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in BMI · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
Monoamine modulators showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).
1 finding from 1 review
Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Nausea · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review